Understanding Lymphoma
CNS Lymphoma

Primary central nervous system (CNS) lymphoma is an aggressive form of non-Hodgkin lymphoma (NHL) in which malignant (cancer) cells are found only in the CNS (the brain and spinal cord). Primary CNS lymphoma can start in the brain, spinal cord, meninges (sheets of tissue that protect the CNS) or the eye. When the lymphoma begins in other parts of the body and spreads to the CNS, it is referred to as secondary CNS lymphoma. In more than 95% of patients with primary CNS lymphoma, the cancer starts in white blood cells (cells that help the body fight infections and cancer) called B-cells.

The cause of primary CNS lymphoma is unknown but having a weakened immune system (for example, people with acquired immunodeficiency syndrome [AIDS] or patients who have undergone organ transplant) may increase the risk of developing the disease. Having one or more of these risk factors does not mean a person will develop primary CNS lymphoma. Most people diagnosed with primary CNS lymphoma have never been exposed to any clearly known risk factors.

The symptoms of CNS lymphoma depend on the part of the CNS that is affected. These can occur suddenly or develop over time, and may include:

- Language problems, like difficulties with finding words or forming sentences, and slurred or slow speech.
- Paralysis (inability to move part of the body).
- Loss of vision or blurred vision.
- Confusion.
- Headaches.
- Vomiting.
- Seizures.
- Personality changes.

Early identification of symptoms and diagnosis of CNS lymphoma is important, followed by a quick start of treatment to reverse neurological deficits (problems in bodily functions due to damage in the brain, spinal cord and nerves) and improve outcomes (how well the patient will do). Upon diagnosis, tests are done to find out which parts of the CNS are involved as well as to determine if there is cancer elsewhere in the body. These can include computed tomography (CT) or positron emission tomography (PET, an imaging procedure that uses a special dye to locate the cancer in the body) scans of the body, magnetic resonance imaging (MRI), an imaging procedure that uses a powerful magnet and X-rays to take detailed pictures of areas inside the body, lumbar puncture (or spinal tap, where a needle is inserted in the lower back to collect a sample of the fluid around the CNS), eye exams, and bone marrow biopsy (a needle is used to take samples of the spongy tissue inside the bones).

Recognizing the symptoms and diagnosing CNS lymphoma early on is very important. This will allow the health care team to start treatment quickly to reverse neurological deficits (problems in bodily functions due to damage in the brain, spinal cord and nerves) and improve the patient’s outcome (how well the patient will do). After CNS lymphoma is diagnosed, the doctors conduct tests to find out which parts of the CNS are involved and if the cancer has spread to other parts of the body, including:

- Computed tomography (CT), an imaging procedure that uses X-rays to take detailed pictures of areas inside the body.
- Positron emission tomography (PET), an imaging procedure that uses a special dye to find out where the cancer is in the body.
- Magnetic resonance imaging (MRI), an imaging procedure that uses a powerful magnet and X-rays to take detailed pictures of areas inside the body.
- Lumbar puncture (or spinal tap), where a needle is inserted in the lower back to collect a sample of the fluid that surrounds the CNS.
- Bone marrow biopsy, where a needle is used to take samples of the spongy tissue inside the bones.

Primary CNS lymphoma usually does not spread beyond the CNS or the eye, but it often relapses (disease comes back after treatment).
TREATMENT OPTIONS

Until the mid-1990s, radiation was the standard therapy (the proper treatment that is widely used by health care providers and accepted by medical experts) for patients with CNS lymphoma. Now, a combination regimen (two or more drugs given at the same time) with high-dose methotrexate and rituximab (Rituxan) is recommended for most patients as induction (initial) treatment. Sometimes, this is given in combination with other agents such as cytarabine (Cytosar), vincristine (Onconvin), procarbazine (Matulane), ifosfamide (Ifex), thiotepa (Tepadina), or temozolomide (Temodar). This initial treatment is often followed by other regimens or consolidation therapies (treatments given once the cancer has disappeared after initial treatment, to kill any cancer cells that may be left in the body), to reduce the risk of relapse. These consolidation therapies include:

- High-dose chemotherapy alone such as cytarabine (Cytosar).
- Cytarabine (Cytosar) and etoposide (Etopos, Toposar).
- High-dose chemotherapy (including thiotepa) with autologous stem cell transplant (patient's own stem cells are infused after high-dose chemotherapy). For more information about stem cell transplantation, please see the Understanding Cellular Therapy guide on LRF's website (lymphoma.org/publications).

Whole brain radiation therapy (WBRT). WBRT is seldom used in patients over the age of 65 because of permanent and progressive neurological complications (for example, loss of memory, problems with balance, or muscle coordination).

TREATMENTS UNDER INVESTIGATION

Many treatments (also referred to as investigational drugs) are currently being tested in clinical trials (a type of research study that tests how well new treatments work) in patients with primary CNS lymphoma. Results from these clinical trials may improve or change the current standard of care (the proper treatment that is widely used by healthcare professionals and accepted by medical experts). The table below lists some of these investigational drugs that can be accessed through a clinical trial.

Treatment options may change as new treatments are discovered and current treatments are improved. Because today's scientific research is continuously evolving, it is important that patients check with their physician or with the Lymphoma Research Foundation (LRF) for any treatment updates that may have recently appeared. It is also very important that patients consult with a specialist to clear up any questions.

<table>
<thead>
<tr>
<th>Agent (Drug)</th>
<th>Class (Type of treatment)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abemaciclib (Verzenio)</td>
<td>Targeted therapy; CDK inhibitor</td>
</tr>
<tr>
<td>Ibrutinib (Imbruvica)</td>
<td>Targeted therapy; BTK inhibitor</td>
</tr>
<tr>
<td>Lenalidomide (Revlimid)</td>
<td>Immunotherapy; immunomodulatory drug</td>
</tr>
<tr>
<td>Nivolumab (Opdivo)</td>
<td>Immunotherapy; immune checkpoint inhibitor, anti-PD-1</td>
</tr>
<tr>
<td>Obinutuzumab (Gazyva)</td>
<td>Immunotherapy; monoclonal antibody, anti-CD20</td>
</tr>
<tr>
<td>Tafasitamab (Monjuvi)</td>
<td>Immunotherapy; monoclonal antibody, anti-CD19</td>
</tr>
<tr>
<td>Pembrolizumab (Keytruda)</td>
<td>Immunotherapy; immune checkpoint inhibitor, anti-PD-1</td>
</tr>
<tr>
<td>Copanlisib (Aliqopa)</td>
<td>Targeted therapy; kinase inhibitor</td>
</tr>
<tr>
<td>Acalabrutinib (Calquence)</td>
<td>Targeted therapy; BTK inhibitor</td>
</tr>
<tr>
<td>Orelabrutinib (ICP-022)</td>
<td>Targeted therapy; BTK inhibitor</td>
</tr>
<tr>
<td>Zanubrutinib (Brukinsa)</td>
<td>Targeted therapy; BTK inhibitor</td>
</tr>
<tr>
<td>Paxalisib (GDC-0084)</td>
<td>Targeted therapy; PI3K/mTOR inhibitor</td>
</tr>
<tr>
<td>Tirabrutinib (ONO-4059)</td>
<td>Targeted therapy; BTK inhibitor</td>
</tr>
<tr>
<td>Lisocabtagene maraleucel (Breyanzi)</td>
<td>Immunotherapy; CAR T-cell therapy, anti-CD19</td>
</tr>
</tbody>
</table>

BTK, Bruton's kinase; CDK, cyclin-dependent kinase; PD-1, programmed cell death protein-1; PI3K/mTOR, phosphatidylinositol-3-kinase/mammalian target of rapamycin.
**CLINICAL TRIALS**

Clinical trials are important in identifying effective drugs and determining the best treatment doses for patients with lymphoma. Because CNS lymphoma is a rare disease, clinical trials are very important to discover treatments that are more effective and less toxic. The rarity of the disease also means that the most recent treatments are often available only through clinical trials.

Patients interested in participating in a clinical trial should view the Understanding Clinical Trials fact sheet on LRF’s website (visit lymphoma.org/publications), and the Clinical Trials Search Request Form at lymphoma.org, talk to their physician, or contact the LRF Helpline for an individualized clinical trial search by calling (800) 500-9976 or emailing helpline@lymphoma.org.

**FOLLOW-UP**

Patients with CNS lymphoma should have regular visits with their physician. During these visits, medical tests (such as blood tests, MRI scans of the brain and/or spine) and eye (ophthalmological) examination may be required to evaluate the need for additional treatment.

Some treatments can cause long-term side effects (occur during treatment and continue for months or years) or late side effects (appear only months, years or decades after treatment has ended). These can vary depending on the following factors:

- Duration of treatment (how long was the treatment given).
- Frequency of treatment (how often was the treatment administered).
- Type of treatment given.
- Age and gender of the patient.
- Patient overall health at the time of treatment.

A physician will check for these side effects during follow-up care. Visits may become less frequent the longer the patient remains in remission (no sign or symptoms of cancer).

Patients and their caregivers are encouraged to keep copies of all medical records. These include test results as well as information on the types, amounts, and duration of all treatments received. Medical records are important for keeping track of any side effects resulting from treatment or potential disease recurrences. LRF’s award-winning Focus On Lymphoma mobile app (lymphoma.org/mobileapp) and the Lymphoma Care Plan (lymphoma.org/publications) can help patients manage this documentation.

**LYMPHOMA CARE PLAN AND PATIENT EDUCATION PROGRAMS**

Keeping your information in one location can help you feel more organized and in control. This also makes it easier to find information pertaining to your care and saves valuable time.

LRF’s Lymphoma Care Plan document organizes information on your health care team, treatment regimen, and follow-up care. You can also keep track of health screenings and any symptoms you experience to discuss with your health care provider during future appointments. The Lymphoma Care Plan document can be accessed by visiting lymphoma.org/publications. LRF also offers a variety of educational activities, including live meetings and webinars for individuals looking to learn directly from lymphoma experts. To view our schedule of upcoming programs, please visit lymphoma.org/programs.
Understanding Lymphoma

LRF Fact Sheet Series is published by the Lymphoma Research Foundation (LRF) for the purpose of informing and educating readers. Facts and statistics were obtained using published information, including data from the Surveillance, Epidemiology, and End Results (SEER) Program. Because each person’s body and response to treatment is different, no individual should self-diagnose or embark upon any course of medical treatment without first consulting with his or her physician. The medical reviewer, the medical reviewer’s institution, and LRF are not responsible for the medical care or treatment of any individual.

LRF appreciates the expertise and review of our Editorial Committee:

Leo I. Gordon, MD, FACP
Co-Chair
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Kristie A. Blum, MD
Co-Chair
Emory University School of Medicine
Jennifer E. Amengual, MD
Columbia University
Carla Casulo, MD
University of Rochester Medical Center
Alex Herrera, MD
City of Hope
Shana Jacobs, MD
Children’s National Hospital
Patrick Connor Johnson, MD
Massachusetts General Hospital
Manali Kamdar, MD
University of Colorado
Ryan C. Lynch, MD
University of Washington
Peter Martin, MD
Weill Cornell Medicine
Neha Mehta-Shah, MD, MSCI
Washington University School of Medicine in St. Louis
M. Lia Palomba, MD
Memorial Sloan Kettering Cancer Center
Pierluigi Porcu, MD
Thomas Jefferson University
Sarah Rutherford, MD
Weill Cornell Medicine

LRF FOCUS ON LYMPHOMA MOBILE APP

Focus on Lymphoma is the first app to provide patients and their caregivers with tailored content based on lymphoma subtype, and actionable tools to better manage diagnosis and treatment. Comprehensive lymphoma management, conveniently in one secure and easy-to-navigate app, no matter where you are on the care continuum. Get the right information, first, with resources from the entire Lymphoma Research Foundation content library, use unique tracking and reminder tools, and connect with a community of specialists and patients. To learn more this resource, visit our website at lymphoma.org/mobileapp, or contact the LRF Helpline at 800-500-9976 or helpline@lymphoma.org.

LRF Helpline

The LRF Helpline staff are available to answer your general questions about lymphoma and treatment information, as well as provide individual support and referrals to you and your loved ones. Callers may request the services of a language interpreter. LRF also offers a one-to-one peer support program called the Lymphoma Support Network and clinical trials information through our Clinical Trials Information Service. For more information about any of these resources, visit our website at lymphoma.org, or contact the LRF Helpline at (800) 500-9976 or helpline@lymphoma.org.

Para información en Español, por favor visite lymphoma.org/es. (For Information in Spanish please visit lymphoma.org/es).

Supported through grants from:

Understanding Lymphoma fact sheet series is published by the Lymphoma Research Foundation (LRF) for the purpose of informing and educating readers. Facts and statistics were obtained using published information, including data from the Surveillance, Epidemiology, and End Results (SEER) Program. Because each person’s body and response to treatment is different, no individual should self-diagnose or embark upon any course of medical treatment without first consulting with his or her physician. The medical reviewer, the medical reviewer’s institution, and LRF are not responsible for the medical care or treatment of any individual.

© 2023 Lymphoma Research Foundation

Last updated 2023